

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A method of modifying beta-amyloid-induced vasoactivity in individuals with Alzheimer's Disease or other vascular-related diseases or disorders, in which said vascular-related diseases or disorders are selected from the group consisting of cerebral amyloid angiopathy, vascular amyloidosis, hypertension and vasospasm associated with severe post-traumatic head injury, comprising antagonizing the secretory phospholipase A2/arachidonic acid/5-lipoxygenase/cyclo-oxygenase-2 pro-inflammatory pathway by administering a pharmaceutically effective amount of oleyloxyethylphosphocholine to the individual in an amount ranging from between 0.1 ~~µg~~ mg to 10 mg/kg body weight/day.

2. (Cancelled).

3. (Previously Presented) The method according to claim 1, further defined as down-regulating a soluble A β pro-inflammatory pathway.

4-22. (Canceled)

23. (Previously Presented) The method of claim 1, wherein the vascular-related disease or disorder is cerebral amyloid angiopathy.

24. (Previously Presented) The method of claim 1, wherein the vascular-related disease or disorder is vascular amyloidosis.

25. (Previously Presented) The method of claim 1, wherein the vascular-related disease or disorder is hypertension.

26. (Previously Presented) The method of claim 1, wherein the vascular-related disease or disorder is vasospasm associated with severe post-traumatic head injury.

27. (Currently Amended) The method of claim 1, wherein oleyloxyethylphosphocholine ~~the secretory phospholipase A2-inhibitor~~ is administered orally, subcutaneously, parenterally, intraperitoneally, intranasally or by implant.

28. (Currently Amended) The method of claim 1, wherein oleyloxyethylphosphocholine ~~the secretory phospholipase A2-inhibitor~~ is administered orally.

29. (Currently Amended) The method of claim 28, wherein oleyloxyethylphosphocholine ~~the secretory phospholipase A2-inhibitor~~ is administered in a pharmacological formulation in the form of a tablet, suspension, solution, emulsion, capsule, powder, or syrup.

30. (Previously Presented) A method of treating cerebral amyloid angiopathy, vascular amyloidosis, hypertension or vasospasm associated with severe post-traumatic head injury in an individual, the method comprising administering a pharmaceutically effective amount of oleyloxyethylphosphocholine to the individual.